ENVB supply chain intelligence for Enveric Biosciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ARIES-SCIENCE-AND-TECHNOLOGY-LLC | ARIES-SCIENCE-AND-TECHNOLOGY-LLC | 92% | On July 10, 2024, Akos entered into an Exclusive License Agreement with Aries Science and Technology, LLC, an Ohio limited liability company ('Aries'), pursuant to which Akos granted Aries a license … |
| DIVERSE-BIOTECH-INC | DIVERSE-BIOTECH-INC | 90% | A portfolio of cannabinoid conjugate technology licensed in from Diverse Biotech, Inc., is sublicensed to Restoration Biologics, LLC as part of the licenses to Restoration Biologics, LLC |
| TEOTEC-PHARMA | TEOTEC-PHARMA | 85% | Subsequent to the execution of the License Agreement, Aries transferred the licensed rights to its wholly owned subsidiary, Teotec Pharma. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MYCOMEDICA-LIFE-SCIENCES-PBC | MYCOMEDICA-LIFE-SCIENCES-PBC | 92% | On November 7, 2024, the Company entered into an Out-Licensing Agreement with MycoMedica Life Sciences, PBC, a Delaware public benefit corporation ('MycoMedica'), pursuant to which the Company will o… |
| RESTORATION-BIOLOGICS-LLC | RESTORATION-BIOLOGICS-LLC | 92% | The other patent family relates to cannabinoid conjugates in combination with COX-2 inhibitors for treatment of pain and joint disease, is licensed under two separate licenses for pharmaceutical and … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ENVB-DEBT-9320 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| ENVB-DEBT-9319 | Warrants outstanding: 153060 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ENVB-OWNER-CITIGROUP-INC | Citigroup Inc. | 95% | 13F/ownership overlay lists Citigroup Inc.; shares held 2,276; ownership 0.12%; value $4,142; as of 2025-12-31. |
| ENVB-OWNER-WELLS-FARGO-COMPANY | Wells Fargo & Company | 95% | 13F/ownership overlay lists Wells Fargo & Company; shares held 1; value $1; as of 2025-12-31. |
| ENVB-OWNER-BANK-OF-AMERICA-CORPORATION | Bank of America Corporation | 95% | 13F/ownership overlay lists Bank of America Corporation; shares held 5; value $9; as of 2025-12-31. |
| ENVB-OWNER-ADVISORSHARES-INVESTMENTS-LLC | AdvisorShares Investments, LLC | 95% | 13F/ownership overlay lists AdvisorShares Investments, LLC; shares held 16,974; ownership 0.90%; value $30,892; as of 2025-12-31. |
| ENVB-OWNER-TOWER-RESEARCH-CAPITAL-LLC-TRC | Tower Research Capital LLC (TRC) | 95% | 13F/ownership overlay lists Tower Research Capital LLC (TRC); shares held 1,917; ownership 0.10%; value $3,488; as of 2025-12-31. |
| ENVB-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 51; value $92; as of 2025-12-31. |
| ENVB-OWNER-SBI-SECURITIES-CO-LTD | SBI Securities Co., Ltd. | 95% | 13F/ownership overlay lists SBI Securities Co., Ltd.; shares held 49; value $89; as of 2025-12-31. |
| ENVB-OWNER-NATIONAL-BANK-OF-CANADA-FI | National Bank of Canada/FI/ | 95% | 13F/ownership overlay lists National Bank of Canada/FI/; shares held 1; value $1; as of 2025-12-31. |
| ENVB-OWNER-UBS-GROUP-AG | UBS Group AG | 95% | 13F/ownership overlay lists UBS Group AG; shares held 2,895; ownership 0.15%; value $5,268; as of 2025-12-31. |
| ENVB-OWNER-DANSKE-BANK-A-S | Danske Bank A/s | 95% | 13F/ownership overlay lists Danske Bank A/s; shares held 1; value $1; as of 2025-12-31. |